MONDAY, Nov. 30, 2020 (HealthDay News) — Patients with type 2 diabetes (T2D) with optimally managed risk factor control have increased cardiovascular disease (CVD) risk compared with controls without diabetes, according to a study published in the Nov. 17 issue of Circulation.
Alison K. Wright, Ph.D., from the University of Manchester in the United Kingdom, and colleagues conducted a retrospective cohort study to examine the correlation between risk factor control and CVD risk in T2D. Data were included for 101,749 individuals with T2D matched to 378,938 controls without diabetes from the Clinical Practice Research Datalink (CPRD) and 330,892 people with T2D in the Scottish Care Information-Diabetes dataset (SCI-Diabetes).
The researchers found that CVD events occurred among 27 percent of CPRD individuals with T2D, 31 percent of SCI-Diabetes individuals with T2D, and 19 percent of CPRD controls. Compared with CPRD controls, the risk for CVD events was increased for CPRD individuals with T2D who had optimal risk factor control (adjusted hazard ratio, 1.21). The pooled hazard ratios for CVD associated with five risk factors being elevated versus optimal risk factor control were 1.09 and 1.96 for people with and without cardiorenal disease, respectively, in T2D participants from CPRD and SCI-Diabetes. Compared with those without cardiorenal disease, those with cardiorenal disease were younger and more likely to have suboptimal risk factor control but had fewer prescriptions for risk factor-modifying medications.
“People with type 2 diabetes should be treated for cardiovascular risk factors as early as possible, regardless of whether they have cardiovascular disease or not,” Wright said in a statement.
Two authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2020 HealthDay. All rights reserved.
